臨床試験

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

NCT: NCT04559685 · TERMINATED

NCT識別子NCT04559685

ステータスTERMINATED

開始日2021-03-15

完了2024-11-10

SponsorNader Sanai (OTHER)

First posted2020-09-23

Last updated2026-05-14

概要

A Phase 0 single center, first in human, open-label study of ascending energy doses of sonodynamic therapy (SDT) utilizing the MRgFUS combined with intravenous ALA to assess safety and efficacy in up to 45 participants with recurrent HGG. Eligible participants who are scheduled for resection will be administered intravenous (IV) aminolevulinic acid HCl (ALA) approximately six to seven (6-7) hours prior to receiving sonodynamic therapy (SDT).

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。